References
- Abraham, K., H. Mielke, H. Fromme, W. Volkel, J. Menzel, M. Peiser, F. Zepp, S. N. Willich, and C. Weikert. 2020. Internal exposure to perfluoroalkyl substances (PFASs) and biological markers in 101 healthy 1-year-old children: Associations between levels of perfluorooctanoic acid (PFOA) and vaccine response. Arch. Toxicol. 94:2131–47. doi:https://doi.org/10.1007/s00204-020-02715-4.
- Alkhalawi, E., M. Kasper-Sonnenberg, M. Wilhelm, W. Völkel, and J. Wittsiepe. 2016. Perfluoroalkyle acids (PFAAs) and anthropometric measures in the first year of life: Results from the Duisburg birth cohort. J. Toxicol. Environ. Health Part A 79:1041–49. doi:https://doi.org/10.1080/15287394.2016.1219552.
- Angelini, G., S. Gardelia, M. Ardy, M. R. Ciriolo, G. Filomini, G. DiTrapani, F. Clarke, R. Sitia, and A. Rubartelli. 2002. Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation. Proc. Natl. Acad. Sci. USA. 99:1491–98. doi:https://doi.org/10.1073/pnas.022630299.
- Appel, M., M. Forsthuber, R. Ramos, R. Widhalm, S. Granitzer, M. Uhl, M. Hengstschlläger, T. Stamm, and C. Gundacker. 2022. The transplacental transfer efficiency of per-and polyfluoroalkyl substances (PFAS): A first meta-analysis. J Toxicol Environ Health B 25:23–42. doi:https://doi.org/10.1080/10937404.2021.2009946.
- Brieger, A., N. Bienefeld, R. Hasan, R. Goerlich, and H. Haasa. 2011. Impact of perfluorooctanesulfonate and perfluoroctanoic acid on human peripheral leukocytes. Toxicol. in Vitro 25:960–68. doi:https://doi.org/10.1016/j.tiv.2011.03.005.
- Bulka, C. M., V. Avula, and R. C. Fry. 2021. Association of exposure to perfluoroalkyl substances individually and in mixtures with persistent infections: Recent findings from NHANES 1999-2016. Environ. Pollut. 275:116619. doi:https://doi.org/10.1016/j.envpol.2021.116619.
- Burchiel, S. W., N. L. Kerkvliet, F. Gerberick, D. A. Lawrence, and G. S. Ladics. 1997. Assessment of immunotoxicity by multiparameter flow cytometry. Fundam. Appl. Toxicol 38:38–54. doi:https://doi.org/10.1006/faat.1997.2325.
- Callard, R. E., and C. M. Smith. 1981. Histocompatibility requirements for T cell help in specific in vitro antibody responses to influenza virus by human blood lymphocytes. Eur. J. Immunol. 11:206–12. doi:https://doi.org/10.1002/eji.1830110309.
- Caruso, A., S. Licenziati, M. Corulli, A. D. Canaris, M. A. De Francesco, S. Fiorentini, L. Peroni, F. Fallacara, F. Dima, A. Balsari, et al. 1997. Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation. Cytometry 27:71–76. doi:https://doi.org/10.1002/(SICI)1097-0320(19970101)27:1<71::AID-CYTO9>3.0.CO;2-O.
- Catelan, D., A. Biggeri, F. Russo, D. Gregori, G. Pitter, F. Da Re, T. Fletcher, and C. Canova. 2021. Exposure to perfluoroalkyl substances and mortality for COVID-19: A spatial ecological analysis in the Veneto region (Italy). Environ. Res. Public Health 18:2734. doi:https://doi.org/10.3390/ijerph18052734.
- Chang, E. T., H.-O. Adami, P. Bofffetta, H. J. Wedner, and J. S. Mandel. 2016. A critical review of perfluorooctanoate and perfluorooctanesulfonate exposure and immunological health conditions in humans. Crit. Rev. Toxicol. 46:279–331. doi:https://doi.org/10.3109/10408444.2015.1122573.
- Chen, X., S. Liu, M. U. Goraya, M. Maarouf, S. Huang, and J.-L. Chen. 2018. Host immune response to influenza A virus infection. Front Immunol 9:320. doi:https://doi.org/10.3389/fimmu.2018.00320.
- Corsini, E., A. Avogadro, V. Galbiati, M. dell’Agli, M. Marinovich, C. L. Galli, and D. R. Germolec. 2011. In vitroevaluation of the immunotoxic potential of perfluorinated compounds (PFCs). Toxicol. Appl. Pharmacol 250:108–16. doi:https://doi.org/10.1016/j.taap.2010.11.004.
- Corsini, E., E. Sangiovanni, A. Avogadro, V. Galbiati, B. Viviani, M. Marinovich, C. L. Galli, M. Dell’Agli, and D. R. Germolec. 2012. In vitro characterization of the immunotoxic potential of several perfluorinated compounds (PFCs). Toxicol. Appl. Pharmacol. 58:248–55. doi:https://doi.org/10.1016/j.taap.2011.11.004.
- Corsini, E., R. W. Luebke, D. R. Germolec, and J. C. DeWitt. 2014. Perfluorinated compounds: Emerging POPs with potential immunotoxicity. Toxicol. Lett 230:263–70. doi:https://doi.org/10.1016/j.toxlet.2014.01.038.
- Corton, J. C., M. L. Cunningham, B. T. Hummer, C. Lau, B. Meek, J. M. Peters, J. A. Popp, L. Rhomberg, J. Seed, and J. E. Klaunug. 2014. Mode of action framework analysis for receptor-mediated toxicity: The peroxisome proliferator-activated receptor alpha (PPARα) as a case study. Crit. Rev. Toxicol. 44:1–49. doi:https://doi.org/10.3109/10408444.2013.835784.
- DeWitt, J. C., C. B. Copeland, M. J. Strynar, and R. W. Luebke. 2008. Perfluorooctanoic acid-induced immunomodulation in adult C57BL/6J or C57BL/6N female mice. Environ. Health Perspect. 116:644–50. doi:https://doi.org/10.1289/ehp.10896.
- DeWitt, J. C., M. M. Peden-Adams, J. M. Keller, and D. R. Germolec. 2012. Immunotoxicity of perfluorinated compounds: Recent developments. Toxicol. Pathol. 40:300–11. doi:https://doi.org/10.1177/0192623311428473.
- DeWitt, J. C., W. C. Williams, N. J. Creech, and R. W. Luebke. 2016. Suppression of antigen-specific antibody responses in mice exposed to perfluorooctanoic acid: Role of PPAPα and T- and B cell targeting. J. Immuntoxicol. 13:38–45. doi:https://doi.org/10.3109/1547691X.2014.996682.
- DeWitt, J. C., S. J. Blossom, and L. A. Schaider. 2019. Exposure to per-fluoroalkyl and polyfluoroalkyl substances leads to immunotoxicity: Epidemiological and toxicological evidence. J. Expo. Sci. Environ. Epidemiol. 29:148–56. doi:https://doi.org/10.1038/s41370-018-0097-y.
- EFSA [European Food Safety Authority]. 2020. EFSA Panel on Contaminants in the Food Chain (CONTAM panel). Schrenk, D., M. Bignami, L. Bodin, J. K. Chipman, J. del Mazo, B. Grasi-Knapp, C. Hogstrand, L. Hoogenboom, J-C. Leblanc, S. Nebbia, E. Nielson, E. Ntzani, A. Peterson, S. Sand, C. Vleminckx, H. Wallace, L. Barregard, J-P. Cravedi, T. I. Haldorsson, L. S. Haug, N. Johansson, H. K. Knutson, M. Rose, A-C. Roudot, H. V. Loveren, G. Vollmer, K. Mackay, F. Riolo, and T. Schwerdtle. 2020. Risk to human health related to the presence of perfluoroalkyl substances in food. EFSA J 18: 6223. doi:https://doi.org/10.2903/j.efsa.2020.6223.
- Elcombe, C. R., B. M. Elcombe, J. R. Foster, D. G. Farrer, R. Jung, S. C. Chang, G. L. Kennedy, and J. L. Butenhoff. 2010. Hepatocellular hypertrophy and cell proliferation in Sprague-Dawley rats following dietary exposure to ammonium perfluorooctanoate occurs through increased activation of the xenosensor nuclear receptors PPARα and CAR/PXR. Arch. Toxicol. 84:787–98. doi:https://doi.org/10.1007/s00204-010-0572-2.
- Emmett, E. A., F. S. Shofer, H. Zhang, D. Freeman, C. Desai, and L. M. Shaw. 2006a. Community exposure to perfluorooctanoate: Relationships between serum concentrations and exposure sources. J. Occup. Environ. Med. 48 (8):759–70. doi:https://doi.org/10.1097/01.jom.0000232486.07658.74.
- Emmett, E. A., H. Zhang, F. S. Shofer, D. Freeman, N. V. Rodway, C. Desai, and L. M. Shaw. 2006b. Community exposure to perfluorooctanoate: Relationships between serum levels and certain health parameters. J. Occup. Environ. Med. 48 (8):771–79. doi:https://doi.org/10.1097/01.jom.0000233380.13087.37.
- Garg, S. K., Z. Yan, V. Vitvitsky, and R. Bannerjee. 2011. Differential Dependence on Cysteine from Transsulfuration versus Transport During T Cell Activation. Antioxid. Redox. Signal 15 (1):39–47. doi:https://doi.org/10.1089/ars.2010.3496.
- Gmünder, H., H. P. Eck, B. Benninghoff, S. Roth, and W. Dröge. 1990. Macrophages regulate intracellular glutathione levels of lymphocytes. Evidence for an immunoregulatory role of cysteine. Cell. Immunol. 129 (1):32–46. doi:https://doi.org/10.1016/0008-8749(90)90184-s.
- Gmünder, H., H.-P. Eck, and W. Dröge. 1991. Low membrane transport activity for cystine in resting and mitogenically stimulated human lymphocyte preparations and human T cell clones. Eur. J. Biochem. 201 (1):113–17. doi:https://doi.org/10.1111/j.1432-1033.1991.tb16263.x.
- Grandjean, P., E. W. Andersen, E. Budtz-Jorgensen, F. Nielsen, K. Molbak, P. Weihe, and C. Heilmann. 2012. Serum vaccine antibody concentrations in children exposed to perfluorinated compounds. J. Am. Med. Assoc. 307:391–97. doi:https://doi.org/10.1001/jama.2011.2034.
- Grandjean, P., C. Heilmann, P. Weihe, F. Nielsen, U. B. Mogensen, A. Timmermann, and E. Budtz-Jorgensen. 2017a. Estimated exposures to perfluorinated compounds in infancy predict attenuated vaccine antibody concentrations at age 5-years. J. Immunotoxicol. 14 (1):188–95. doi:https://doi.org/10.1080/1547691X.2017.1360968.
- Grandjean, P., C. Heilmann, P. Weihe, F. Nielsen, U. B. Mogensen, and E. Budtz-Jorgensen. 2017b. Serum vaccine antibody concentrations in adolescents exposed to perfluorinated compounds. Environ. Health Perspect. 125 (7). doi:https://doi.org/10.1289/ehp275.
- Granum, B., L. S. Haug, E. Namork, S. B. Stølevik, C. Thomsen, I. S. Aaberge, H. van Loveren, M. Løvik, and U. C. Nygaard. 2013. Pre-natal exposure to perfluoroalkyl substances may be associated with altered vaccine antibody levels and immune-related health outcomes in early childhood. J. Immunotoxicol. 10 (4):373–79. doi:https://doi.org/10.3109/1547691X.2012.755580.
- Guruge, K. S., H. Hikono, N. Shimada, K. Murakami, J. Hasegawa, L. W. Y. Yeung, N. Yamanaka, and N. Yamashita. 2009. Effect of perfluorooctane sulfonate (PFOS) on influenza A virus-induced mortality in female B6C3F1 mice. J. Toxicol. Sci. 34 (6):687–91. doi:https://doi.org/10.2131/jts.34.687.
- Hawkes, C. P., and S. Mostoufi-Moab. 2019. Fat-bone interaction within the bone marrow milieu: Impact on hematopoiesis and systemic energy metabolism. Bone 119:57–84. doi:https://doi.org/10.1016/j.bone.2018.03.012.
- Hu, W. Y., P. D. Jones, W. DeCoen, L. King, P. Fraker, J. Newsted, and J. P. Giesy. 2003. Alterations in cell membrane properties caused by perfluorinated compounds. Comp. Biochem. Physiol. Part C: Toxicol. Pharmacol. 135:77–88.
- Hu, W., P. D. Jones, T. Celius, and J. P. Giesy. 2005. Identification of genes responsive to PFOS using gene expression profiling. Environ. Toxicol. Pharmacol. 19 (1):57–70. doi:https://doi.org/10.1016/j.etap.2004.04.008.
- Ji, J., L. Song, J. Wang, Z. Yang, H. Yan, T. Li, L. Yu, L. Jian, F. Jiang, J. Li, et al. 2021. Association between urinary per- and poly-fluoroalkyl substances and COVID-19 susceptibility. Environ. Intl. 153:106524. doi:https://doi.org/10.1016/j.envint.2021.106524.
- Kasten-Jolly, J., and D. A. Lawrence. 2020. In Vitro evaluation of toxicant influences on the immune system. Curr. Prot. Toxicol. 84:e95.
- Kato, K., L.-Y. Wong, L.-T. Jia, Z. Kuklenyik, and A. M. Calafat. 2011. Trends in exposure to polyfluoroalkyl chemicals in the U.S. population: 1999-2008. Environ. Sci. Technol. 45:8037–45. doi:https://doi.org/10.1021/es1043613.
- Keil, D. E. 2015. Immunotoxicity of perfluoroalkylated compounds. In Toxicological effects of perfuoroalkyl and polyfluoroalkyl substances, molecular and integrative toxicology, ed. J. C. DeWitt, 239–48. Switzerland: Springer International Publishing.
- Kinter, A. L., E. J. Godbout, J. P. McNally, I. Sereti, G. A. Roby, M. A. O’Shea, and A. S. Fauci. 2008. The common γ-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J. Immunol. 181 (10):6738–46. doi:https://doi.org/10.4049/jimmunol.181.10.6738.
- Klaunig, J. E., M. A. Babich, K. P. Baetchke, J. C. Cook, J. C. Corton, R. M. David, J. G. DeLuca, D. Y. Lai, R. H. McKee, J. M. Peters, et al. 2003. PPARalpha agonist-induced rodent tumors: Modes of action and human relevance. Crit. Rev. Toxicol. 33:655–780. doi:https://doi.org/10.1080/713608372.
- Klaunig, J. E., B. A. Hocevar, and L. M. Kamendulis. 2012. Mode of action analysis of perfluorooctanoic acid (PFOA) tumorigenicity and human relevance. Reprod. Toxicol. 33 (4):410–18. doi:https://doi.org/10.1016/j.reprotox.2011.10.014.
- Kovacs, B., M. V. Maus, J. L. Riley, G. S. Derimanov, G. A. Koretzky, C. H. June, and T. H. Finkel. 2002. Human CD8 + T cells do not require the polarization of lipid rafts for activation and proliferation. Proc. Natl. Acad. Sci. USA 99 (23):15006–11. doi:https://doi.org/10.1073/pnas.232058599.
- Krieger, J. A., J. C. Landsiedel, and D. A. Lawrence. 1997. Differential in vitro effects of physiologic and atmospheric oxygen tension on normal human peripheral blood mononuclear cell proliferation, cytokine and immunoglobulin production. Int. J. Immunopharmacol. 18 (10):545–52. doi:https://doi.org/10.1016/S0192-0561(96)00057-4.
- Lawrence, D. A., R. J. Colinas, and A. C. Walsh. 1996a. Influence of oxygen partial pressure on human and mouse myeloid cell line characteristics. Fundam. Appl. Toxicol. 29:287–93. doi:https://doi.org/10.1006/faat.1996.0033.
- Lawrence, D. A., R. Song, and P. Weber. 1996b. Surface thiols of human lymphocytes and their changes after in vitro and in vivo activation. J. Leukoc. Biol. 60 (5):611–18. doi:https://doi.org/10.1002/jlb.60.5.611.
- Lee, F., and D. A. Lawrence. 2018. From infections to anthropogenic inflicted pathologies: Involvement of immune balance. J Toxicol Environ Health B 21 (1):24–46. doi:https://doi.org/10.1080/10937404.2017.1412212.
- Lee, J.-K., and S.-H. Kim. 2018. Correlation between mast cell-mediated allergic inflammation and length of perfluorinated compounds. J. Toxicol. Environ. Health Part A 81:302–13. doi:https://doi.org/10.1080/15287394.2018.1440188.
- Li, R., C. Guo, X. Lin, T. F. Chan, K. P. Lai, and J. Chen. 2020. Integrative omics analyses uncover the mechanism underlying the immunotoxicity of perfluorooctanesulfonate in human lymphocytes. Chemosphere 256:127062. doi:https://doi.org/10.1016/j.chemosphere.2020.127062.
- Lundin, J. I., B. H. Alexander, G. W. Olsen, and T. R. Church. 2009. Ammonium perfluorooctanoate production and occupational mortality. Epidemiology 20 (6):921–28. doi:https://doi.org/10.1097/EDE.0b013e3181b5f395.
- Magg, T., and M. H. Albert. 2007. Tracking cell proliferation using the far-red fluorescent dye SNARF-1. Cytometry B Clin Cytom 72B (6):458–64. doi:https://doi.org/10.1002/cyto.b.20180.
- Malek, T. R. 2003. The main function of IL-2 is to promote the development of T regulatory cells. J. Leukoc. Biol. 74 (6):961–65. doi:https://doi.org/10.1189/jlb.0603272.
- Martner, A., J. Aurelius, A. Rydstöm, K. Hellstrand, and E. B. Thorén. 2011. Redox remodeling by dendritic cells protects antigen-specific T cells against oxidative stress. J. Immunol. 167 (12):6243–4248. doi:https://doi.org/10.4049/jimmunol.1102138.
- Messina, J. P., and D. A. Lawrence. 1989. Cell cycle progression of glutathione-depleted human peripheral blood mononuclear cells is inhibited at S phase. J. Immunol. 143:1974–81.
- Midgett, K., M. M. Peden-Adams, G. S. Gilkeson, and D. L. Kamen. 2015. In vitro evaluation of the effects of perfluorooctanesulfonic acid (PFOS) and perfluorooctanoic acid (PFOA) on IL-2 production in human T cells. J. Appl. Toxicol. 35:459–65. doi:https://doi.org/10.1002/jat.3037.
- Morris, D. I., H. G. Jeong, W. D. Stevens, Y. J. Chun, J. G. Karras, and M. P. Holsappie. 1994. Serum modulation of the effects of TCDD on the in vitro antibody response and on enzyme induction in primary hepatocytes. Immunopharmacology 27 (2):93–105. doi:https://doi.org/10.1016/0162-3109(94)90044-2.
- Mosier, D. E. 1969. Cell interactions in the primary immune response in vitro: A requirement for specific cell clusters. J. Exp. Med. 129 (2):351–62. doi:https://doi.org/10.1084/jem.129.2.351.
- Mumtaz, M. M., M. C. Buser, and H. R. Pohl. 2021. Per- and polyfluoroalkyl mixtures toxicity assessment “proof-of-concept” illustration for the hazard index approach. J. Toxicol. Environ. Health Part A 84 (13):553–67. doi:https://doi.org/10.1080/15287394.2021.1901251.
- Nagafuku, M., K. Okuyama, Y. Onimaru, A. Suzuki, Y. Odagiri, T. Yamashita, K. Iwasaki, M. Fujiwara, M. Takayanagi, I. Ohno, et al. 2012. CD4 and CD8 T cells require different membrane gangliosides for activation. Proc. Natl. Acad. Sci. USA 109:E336–E342. doi:https://doi.org/10.1073/pnas.1114965109.
- Ojo, A. F., C. Peng, and J. C. Ng. 2020. Combined effects and toxicological interactions of perfluoroalkyl and polyfluoroalkyl substances mixtures in human liver cells (HepG2). Environ. Pollut. 263:114182. doi:https://doi.org/10.1016/j.envpol.2020.114182.
- Olsen, G. W., J. M. Burris, M. M. Burlew, and J. H. Mandel. 2003. Epidemiological assessment of worker serum perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) concentrations and medical surveillance examinations. J. Occup. Environ. Med. 45 (3):260–70. doi:https://doi.org/10.1097/01.jom.0000052958.59271.10.
- Olsen, G. W., J. M. Burris, D. J. Ehresman, J. W. Froehlich, A. W. Seacat, J. L. Butenhoff, and L. R. Zobel. 2007. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ. Health Perspect. 115 (9):1298–305. doi:https://doi.org/10.1289/ehp.10009.
- Peden-Adams, M. M., J. M. Keller, J. G. EuDaly, J. Berger, G. S. Gilkeson, and D. E. Keil. 2008. Suppression of humoral immunity in mice following exposure to perfluorooctane sulfonate. Toxicol. Sci. 104 (1):144–54. doi:https://doi.org/10.1093/toxsci/kfn059.
- Pennings, J. L. A., D. G. J. Jennen, U. C. Nygaard, E. Namork, L. S. Haug, H. van Loveren, and B. Granum. 2016. Cord blood gene expression supports that prenatal exposure to perfluoroalkyl substances causes depressed immune functionality in early childhood. J. Immunotoxicol 13 (2):173–80. doi:https://doi.org/10.3109/1547691X.2015.1029147.
- Pilkerton, C. S., G. R. Hobbs, C. Lilly, S. S. Knox, and J. Meliker. 2018. Rubella immunity and serum perfluoroalkyl substances: Sex and analytic strategy. PLoS ONE 13 (9):e0203330. doi:https://doi.org/10.1371/journal.pone.0203330.
- Qazi, M. R., D. Nelson, J. W. DePierre, and M. Abedi-Valugerdi. 2012. High-dose dietary exposure of mice to perfluorooctanoate or perfluorooactanesulfonate exerts toxic effects on myeloid and B-lymphoid cells in the bone marrow and these effects are partially dependent on reduced food consumption. Food Chem. Toxicol. 50 (9):2955–63. doi:https://doi.org/10.1016/j.fct.2012.06.023.
- Schroeder, K., P. J. Hertzog, T. Ravasi, and D. A. Hume. 2004. Interferon-γ: An overview of signals, mechanisms, and functions. J. Leukoc. Biol. 75:163–89. doi:https://doi.org/10.1189/jlb.0603252.
- Sebo, Z. I., E. Rendina-Ruedy, G. P. Ables, D. M. Lindskog, M. S. Rodeheffer, P. K. Fazeli, and M. C. Horowitz. 2019. Bone marrow adiposity: Basic and clinical implications. Endocr. Rev. 40:1187–206. doi:https://doi.org/10.1210/ER2018-00138.
- Soloff, A. C. B. J., N. D. Wolf, W. D. Muir, S. Courtney, G. Hardiman, G. D. Bossart, and P. A. Fair. 2017. Environmental perfluorooctane sulfonate exposure drives T cell activation in bottlenose dolphins. J. Appl. Toxicol. 37:1108–16. doi:https://doi.org/10.1002/jat.3465.
- Steenland, K., T. Fletcher, and D. A. Savitz. 2010. Epidemiologic evidence on the health effects of perfluorooctanoic acid (PFOA). Environ. Health Perspect. 118 (8):1100–08. doi:https://doi.org/10.1289/ehp.0901827.
- Stein, C. R., Y. Ge, M. S. Wolff, X. Ye, A. M. Calafat, T. Kraus, and T. M. Moran. 2016. Perfluoroalkyl substance serum concentrations and immune response to FluMist vaccination among healthy adults. Environ. Res. 149:171–78. doi:https://doi.org/10.1016/j.envres.2016.05.020.
- Sun, Y., K. Yang, T. Bridal, and A. G. Ehrhardt. 2016. Robust Ki67 detection in human blood by flow cytometry for clinical studies. Bioanalysis 8 (23):2399–413. doi:https://doi.org/10.4155/bio-2016-0194.
- Sunderland, E. M., X. C. Hu, C. Dassuncao, A. K. Tokranov, C. C. Wagner, and J. G. Allen. 2019. A review of the pathways of human exposure to poly- and perfluoroalkyl substances (PFASs) and present understanding of health effects. J. Exposure Sci. Environ. Epidemiol. 29 (2):131–47. doi:https://doi.org/10.1038/s41370-018-0094-1.
- United States Department of Health and Human Services-National Toxicology Program [USDHHS-NTP], 2016. Systemic review of immunotoxicity associated with exposure to perfluorooctanoic acid (PFOA) or perfluorooctane sulfonate (PFOS) accessed 6. 8.20. https://NTP.NIEHS.NIH.GOV/NTP/OHAT/PFOA_PFOS/PFOA_PFOSMONOGRAPH_508.PDF
- Von Holst, H., P. Nayak, Z. Dembek, S. Buehler, D. Echeverria, D. Fallacara, and L. John. 2021. Perfluoroalkyl substances exposure and immunity, allergic response, infection, and asthma in children: Review of epidemiologic studies. Heliyon 7 (10):e08160. doi:https://doi.org/10.1016/j.heliyon.2021.e08160.
- Wang, Y., L. Wang, Y. Liang, W. Qiu, J. Zhang, Q. Zhou, and G. Jiang. 2011. Modulation of dietary fat on the toxicological effects in thymus and spleen in BALB/c mice exposed to perfluorooctane sulfonate. Toxicol. Lett 204:174–82. doi:https://doi.org/10.1016/j.toxlet.2011.04.029.
- Wirth, J. R., M. M. Peden-Adams, N. D. White, G. D. Bossart, and P. A. Fair. 2014. In vitro PFOS exposure on immune endpoints in bottlenose dolphins (Tursiops truncatus) and mice. J. Appl. Toxicol. 34 (6):658–66. doi:https://doi.org/10.1002/jat.2891.
- Yang, Q., Y. Xie, A. M. Eriksson, B. D. Nelson, and J. W. DePierre. 2001. Further evidence for the involvement of inhibition of cell proliferation and development in thymic and splenic atrophy induced by the peroxisome proliferator perfluorooctanoic acid in mice. Biochem. Pharmacol. 62:1133–40. doi:https://doi.org/10.1016/S0006-2952(01)00752-3.
- Yang, Q., M. Abedi-Valugerdi, Y. Xie, X. Y. Zhaoer, B. D. Nelson, and J. W. DePierre. 2002. Potent suppression of the adaptive immune response in mice upon dietary exposure to the potent peroxisome proliferator, perfluorooctanoic acid. Int. Immunopharmacol. 2:389–97. doi:https://doi.org/10.1016/S1567-5769(01)00164-3.